Previous 10 |
Vancouver, Kelowna, Delta, BC - February 25, 2022 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in Biotech, Cannabis and Mining. Today's stocks have been added to our lists of free sto...
Amylyx Pharmaceuticals (NASDAQ:AMLX), a development-stage pharmaceutical company focused on neurodegenerative diseases announced on Friday that the European regulators have validated the company’s marketing application for AMX0035 in amyotrophic lateral sclerosis (ALS). With the decisi...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”), today announced that its Marketing Authorisation Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for AMX0035 (sodi...
Amylyx Pharmaceuticals (NASDAQ:AMLX) announced on Wednesday that the U.S. Food and Drug Administration (FDA) is set to hold an Advisory Committee meeting to decide on its marketing application for AMX0035, an experimental drug for amyotrophic lateral sclerosis (ALS). According to the company,...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that a virtual meeting of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee to review the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate [PB] and ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs and Co-Founders of Amylyx, will present at the 11 th Annual SVB Leerink Global Healthcare Conference. The conference is being conducted in a virtual format, and the presentation wi...
The Canadian Neuromuscular Disease Registry (CNDR), an independent, academic registry based out of the University of Calgary, and Amylyx Pharmaceuticals (NASDAQ: AMLX) today announced they are partnering on a real‐world evidence generation initiative for Amylyx’ novel inve...
News, Short Squeeze, Breakout and More Instantly...
Amylyx Pharmaceuticals Inc. Company Name:
AMLX Stock Symbol:
NASDAQ Market:
Amylyx Pharmaceuticals Inc. Website:
- Avexitide is a novel, first-in-class GLP-1 receptor antagonist with the potential to treat hyperinsulinemic hypoglycemia - FDA Breakthrough Therapy Designation granted for avexitide for post-bariatric hypoglycemia (PBH) and congenital hyperinsulinism - Acquisition builds on Am...
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that Amylyx’ management team will host a conference call and webcast tomorrow, Wednesday, July 10, 2024, at 8:00 a.m. ET to discuss the acquisition of avexitide from Eiger ...
Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will participate in a fireside chat presentation at the Goldman Sachs 45th Annual Global Healthcare Conference. The conference is being conducted in-person in Miam...